Zantac (A) Case Solution
This Case is about NATIONAL COMPETITIVENESS
PUBLICATION DATE: January 09, 1992
The article discusses the advancement, around the world launch, and subsequential advertising of a brand-new pharmaceutical item which, though it stood for just a small enhancement over the classification leader, not just ended up being the leading item in its classification, however the biggest prescribed pharmaceutical item total globally. Its excellence moved Glaxo, the organization which industried the item and cultivated, from the minors to the leading positions inside the pharmaceutical market.
Related Case Solutions:
The Renault-Nissan Alliance in 2008: Exploiting the Potential of a Novel Organizational Form
Renault Nissan: The Challenge of Sustaining Change
Nissan Motor Co. Ltd.–2002
Selecting a Pharmaceutical Company from Northeast Asia for Investment
Lipitor (A)
CIBC Mellon: Managing a Cross-Border Joint Venture
BP in Russia: Settling the Joint Venture Dispute
Glaxo and Zantac: The Life, Times, and Near Death of the World’s Best-Selling Drug
Zantac (Spanish) Spanish
Energy Devices